New probes to detect lung cancer early
Novel metabolomic contrast probes for human lung cancer characterization
['FUNDING_R01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-10912679
This study is testing new ways to spot lung cancer early by looking at blood and tissue samples, and it's for anyone who wants to help improve how we diagnose and treat this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10912679 on ClinicalTrials.gov |
What this research studies
This research focuses on developing novel metabolomic contrast probes that can help in the early detection of lung cancer by analyzing tissue and blood serum samples. The study aims to validate the effectiveness of these markers by comparing them with samples from healthy individuals and assessing their ability to classify lung cancer accurately. By utilizing advanced techniques like mass spectrometry, the researchers hope to enhance the capability of these probes for better diagnosis and treatment planning. Ultimately, the goal is to identify a serum contrast probe that can detect lung cancer at asymptomatic stages, improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for lung cancer, particularly those with pre-symptomatic conditions.
Not a fit: Patients who are already diagnosed with advanced lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of lung cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in using metabolomic markers for cancer detection, indicating that this approach has potential for success.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FARRAR, CHRISTIAN T — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: FARRAR, CHRISTIAN T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Detection